CJC-1295/Ipamorelin vs Sermorelin: Which Growth Hormone Peptide Is Right for You in 2026

The short answer

CJC-1295/Ipamorelin is a two-peptide stack. The CJC-1295 in this prescription is the no-DAC form, with a roughly 30-minute half-life, not the long-acting DAC form used in the published human trials. Ipamorelin is a ghrelin receptor agonist. Hitting a GHRH receptor and a ghrelin receptor together is an established way to potentiate acute growth hormone release, so a larger GH response than either alone is a reasonable expectation. That is a statement about a hormone level, not about results: no human trial has tested this combination for any clinical outcome.

Sermorelin is a single peptide: the 29-amino acid bioactive fragment of natural GHRH with a 10 to 15 minute half-life. It produces a brief, natural-feeling GH pulse.

Choose CJC-1295/Ipamorelin if you want the strongest GH response from a peptide stack and are targeting body composition, recovery, and sleep depth. Choose sermorelin if you are new to GH peptides, want the gentlest pulse, or are over 50 and prefer a more conservative starting protocol. If lean mass is your primary goal, our guide to the best peptides for muscle growth compares these GH secretagogues against the wider field.

Both are compounded by Optimal Balance Pharmacy under a prescription written by an RxPepsDirect licensed provider in 28 states. CJC-1295/Ipamorelin runs $100 per 10mg+10mg vial; sermorelin runs $80 per 15mg vial. Both last 4 to 6 weeks at standard dosing.

What is CJC-1295/Ipamorelin?

CJC-1295/Ipamorelin is a compounded blend of two growth hormone secretagogues, prescribed and dispensed in a single injectable vial. They act on separate receptors, which is the rationale for combining them, but no controlled human trial has tested the two together, so they are complementary rather than demonstrably synergistic.

CJC-1295 is a 30-amino acid modified analog of growth hormone-releasing hormone (GHRH). The original CJC-1295 was developed in the early 2000s with a drug affinity complex (DAC) modification that extended its half-life to roughly one week. The compounded CJC-1295 used in peptide telehealth today is the no-DAC version, which retains the stabilizing amino acid substitutions but drops the DAC modification, producing a half-life of roughly 30 minutes. The result is a GHRH analog that lasts about three times as long as sermorelin in circulation.

Ipamorelin is a pentapeptide ghrelin receptor agonist. Ghrelin is the body's endogenous hunger and GH-release hormone. Ipamorelin selectively binds the growth hormone secretagogue receptor (GHS-R1a) without significantly elevating cortisol, aldosterone, or prolactin, which are common off-target effects of older ghrelin agonists like GHRP-6 and hexarelin.

When paired, the two peptides hit two different pituitary pathways simultaneously. CJC-1295 stimulates GHRH receptors. Ipamorelin stimulates ghrelin receptors. Co-stimulating both is a recognised way to amplify acute GH release, and it is the basis for combined GHRH-plus-secretagogue protocols used in growth hormone stimulation testing. What has not been measured is this particular pairing, at these doses, in this population, or whether a larger GH pulse produces any clinical benefit here.

See the full CJC-1295/Ipamorelin product page for current pricing and the CJC-1295/Ipamorelin protocol guide for the complete dosing and protocol reference.

What is sermorelin?

Sermorelin is the 29-amino acid N-terminal fragment of natural GHRH. It is the smallest sequence of GHRH that retains full biological activity at the GHRH receptor. Anything shorter than 29 residues loses receptor affinity.

Sermorelin was FDA-approved as the branded drug Geref in 1997 for pediatric growth hormone deficiency and as a diagnostic agent. EMD Serono discontinued the branded product in 2008 for commercial reasons, not safety. Sermorelin remains an FDA-listed active ingredient eligible for compounding by 503A pharmacies under a patient-specific prescription.

The half-life is short: roughly 10 to 15 minutes in circulation. Sermorelin binds GHRH receptors on pituitary somatotrophs and triggers a brief, natural-feeling GH pulse. The short duration mimics the body's own pulsatile pattern more closely than longer-acting GHRH analogs.

See the sermorelin product page for current pricing and the sermorelin protocol guide for the full dosing reference.

Side-by-side comparison

Mechanism: one pathway vs two

Natural growth hormone release in the pituitary is controlled by two opposing hormonal signals: GHRH (which stimulates GH release) and somatostatin (which inhibits it). A third regulator, ghrelin, also stimulates GH release through a separate receptor.

Sermorelin hits one of these signals: GHRH. A sermorelin injection produces a short pulse of GHRH receptor stimulation, the pituitary releases GH, and somatostatin then shuts the response off within 30 to 60 minutes. The pulse is brief, natural, and self-limiting.

CJC-1295/Ipamorelin hits two signals. CJC-1295 stimulates GHRH receptors for roughly 30 minutes (longer than sermorelin). Ipamorelin simultaneously stimulates ghrelin receptors. Co-stimulating both receptors is expected to be additive, and the longer CJC-1295 duration extends the window over sermorelin's. That expectation comes from GHRH-plus-secretagogue pharmacology generally, not from a study of this vial, and it describes GH release rather than any downstream result.

On that reasoning the blend would be expected to drive a larger GH response than sermorelin at comparable doses. It has not been measured head-to-head, and a larger hormone response is not the same as a better outcome, so claims that it delivers deeper sleep, faster recovery or more obvious body-composition change are not supported by trial data for either product. Sermorelin remains closer to a single-signal physiologic mimic, which is why it is often described as the gentler option.

Dosing protocols

CJC-1295/Ipamorelin standard protocol

• Dose: 20 units subcutaneous injection (0.4mg CJC-1295 + 0.4mg Ipamorelin)
• Frequency: 5 nights per week, typically Monday through Friday
• Timing: 30 to 60 minutes before bed, on an empty stomach (food blunts the GH response)
• Cycling: Most providers run continuous protocols with periodic bloodwork. Some clinicians cycle 5-on / 2-off weekly or 8-on / 2-off in 10-week blocks
• Vial duration: 10mg+10mg vial lasts roughly 5 weeks at standard dosing

Sermorelin standard protocol

• Dose: 20 units subcutaneous injection (0.6mg sermorelin)
• Frequency: 5 nights per week, Monday through Friday
• Timing: 30 to 60 minutes before bed, on an empty stomach
• Cycling: Continuous protocols are typical; sermorelin's short half-life means the pulse is naturally self-limiting and tachyphylaxis is less of a concern
• Vial duration: 15mg vial lasts roughly 5 weeks at standard dosing

What the evidence actually shows

The randomized controlled trial base for both peptides is modest compared to FDA-approved synthetic HGH. Most published data come from short trials in specific populations (pediatric GHD, HIV-associated lipodystrophy, age-related GH decline) or from secondary endpoints in trials with different primary outcomes.

What is well-established: both peptides reliably raise serum GH and IGF-1 in healthy adults at clinically used doses. Sermorelin was used as a diagnostic agent precisely because its GH-releasing effect is reproducible. CJC-1295/Ipamorelin produces larger IGF-1 increases than sermorelin at equivalent frequency.

What is reasonable to infer: body composition, recovery, and sleep depth improvements over 8 to 16 weeks are consistent with the known effects of restoring pulsatile GH release in adults with age-related decline. The clinical magnitude is generally smaller than what supraphysiologic HGH produces, which is the point: GH secretagogues preserve the body's own feedback loop rather than overriding it.

What is overstated by marketing: dramatic anti-aging claims, large lean-mass gains in trained athletes, claims of GH levels matching elite-athlete profiles. Neither peptide produces supraphysiologic GH levels at therapeutic doses. The effect is restoration of pulsatile release, not amplification beyond physiologic.

Side effects compared

Both peptides share most of their side-effect profile because they trigger the body's own GH release through the pituitary rather than supplying exogenous synthetic HGH.

Common to both: injection-site flushing or itching, mild water retention in the first 2 to 4 weeks, occasional tingling in hands or feet (peripheral neuropathy from mild fluid shifts), vivid dreams or improved dream recall in the first week.

More common with CJC-1295/Ipamorelin: increased appetite (the Ipamorelin component activates ghrelin receptors, which is the same pathway that drives hunger), mild fasting glucose elevation in patients with insulin resistance, occasional headache in the first week.

Specific to neither: the carpal tunnel, joint aches, and edema that are characteristic of supraphysiologic HGH are uncommon at GH-secretagogue doses because the GH pulse magnitude stays within physiologic range.

Contraindications for both: active malignancy, pituitary tumor, severe diabetic retinopathy, pregnancy or breastfeeding. RxPepsDirect providers screen for these on intake.

Cost comparison

Both peptides are priced at 503A pharmacy wholesale through RxPepsDirect. There is no membership fee, no subscription, no markup. The $39 provider review covers the prescription; you pay the pharmacy directly for the medication.

The pricing gap exists because RxPepsDirect does not mark up the pharmacy product. Subscription clinics and concierge practices bundle the medication, provider time, and program management into a monthly fee. The compounded product is the same in most cases. See the full peptide telehealth comparison.

Who should choose which

Choose CJC-1295/Ipamorelin if

• You want the strongest GH response from a peptide stack
• Your primary goals are body composition (lean mass gain, fat redistribution) and recovery from training
• You want deeper, more obvious sleep improvement
• You have stable fasting glucose and no active appetite issues
• You have used sermorelin and want to try a larger GH stimulus per dose, understanding that neither product has comparative outcome data behind it

Choose sermorelin if

• You are new to peptide therapy and want the gentlest GH support available
• You are over 50 and prefer a conservative starting protocol
• You have appetite control concerns or active weight loss goals
• You have borderline fasting glucose or want the most conservative metabolic profile
• You want the longest FDA history in the peptide class

Consider Sermorelin/Ipamorelin if

RxPepsDirect also offers a Sermorelin/Ipamorelin combination ($100 per 15mg+18mg vial) for patients who want the sermorelin half-life paired with the ghrelin-agonist additive effect. It sits between sermorelin alone and CJC-1295/Ipamorelin on the pulse magnitude spectrum.

How to get a prescription

Both peptides require a prescription from a licensed provider in your state.

1. Choose your peptide on the muscle growth selection and add it to your protocol.
2. Complete the medical intake. Pay the $39 provider review.
3. An RxPepsDirect provider (Dr. Jonathan Snipes, MD or Kim Callender, FNP-BC) reviews your intake within 24 to 48 hours and approves the appropriate protocol.
4. The prescription is sent to Optimal Balance Pharmacy. They compound the product, ship pre-reconstituted, FedEx overnight in a reusable cooled travel case.
5. Refills are per vial with no auto-billing. Re-request when you need the next one.

Related comparisons

For more peptide comparisons in the growth hormone class:

• Tesamorelin vs sermorelin covers the comparison between the strongest GHRH analog (tesamorelin, the only FDA-approved drug in the class) and sermorelin
• Tesamorelin buyer's guide covers the Egrifta-vs-compounded comparison and pricing
• The peptide therapy pillar guide covers the full overview of how peptide therapy works
• Compounded vs research-grade peptides explains why a prescription pathway matters